Effect of High-intensity Interval Training on Low-grade Systemic Inflammation in Obese Young Adults.

NCT05700292 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-10-23

No results posted yet for this study

Summary

Background: Obesity is a multifactorial disease that affects 36% of the Mexican population; it is characterized by the excessive accumulation of adipose tissue in the body, mainly in the abdominal region, conditions that are closely linked to low-grade systemic inflammation (LGSI). Scientific evidence suggests that LGSI can be attenuated by the benefits of regular physical exercise, since such activity has the potential to decrease the concentrations of certain proinflammatory molecules, such as reactive C protein, tumor necrosis factor alpha and interleukin 6. Objective: To analyze the LGSI response when intervening with a high-intensity interval training in young obese adults between 18 to 30 years. Materials and methods: The present study is defined as a simple randomized clinical trial. Participants will be randomized into one of two groups of intervention; 1: High-intensity interval training (HIIT), and the control group with moderate-intensity continuous training (MICT). The interventions will be 3 times a week for 2 months, completing a total of 24 sessions. The HIIT group will carry out the activities at high intensity (85 to 95% maximum heart rate) aerobic type training; density of 1 minute at high interval followed by 2 minutes of low interval with a total time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). While the MICT group will carry out the activities with a moderate intensity (60 to 75% maximum heart rate) aerobic type training reaching a total time of 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). Physical activity will be monitored using a Polar brand heart rate sensor (model H9). Anthropometric, biochemical, and inflammatory assessments will be monitored at baseline, at 4 weeks (mid-intervention), and at 8 weeks (end of intervention). Biochemical parameters will be determined by dry chemistry (Vitros 350), anthropometry by electrical bioimpedance (Inbody 370), and inflammatory markers by blood count and ProQuantum Immunoassay technology. Infrastructure: Institute of Translational Nutrigenomics and Nutrigenomics, University Center for Health Sciences, University of Guadalajara.

Conditions

Interventions

OTHER

High-intensity Interval Training

Training is based on 5 circuits, with intervals of 1 minute (high intensity) by 2 minutes (low intensity), with a total training time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). The high intervals will be performed with the following exercises: squat, reverse lunge \& knee-up, reverse jump and walkout pushup, while the low intervals were performed jogging. The heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate of 85% to 95%. To monitor heart rate during training, a polar brand chest sensor, model H9, will be used.

OTHER

Moderate-intensity continuous training

Continuous aerobic training (jogging). Also, the heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate from 60% to 75% and an increase in training time from 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). To monitor heart rate during training, a polar brand chest sensor, model H9, will be used as well.

Sponsors & Collaborators

  • University of Guadalajara

    lead OTHER

Principal Investigators

  • Erika Martinez-Lopez, PhD · University of Guadalajara

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2023-12-30
Completion
2023-12-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05700292 on ClinicalTrials.gov